Eftilagimod alpha Market Summary

Key Factors Driving Eftilagimod alpha Growth

1. Novel mechanism may provide differentiation from conventional checkpoint inhibitors: Eftilagimod alfa is a soluble LAG-3 protein/MHC class II agonist that activates antigen-presenting cells and subsequently stimulates CD4+ and CD8+ T-cell responses. Unlike LAG-3-blocking antibodies, efti is designed to enhance antigen presentation and prime the immune system, making it particularly attractive as a combination partner with PD-1/PD-L1 inhibitors. Clinical studies have demonstrated increases in activated T cells and immune biomarkers following treatment.

2. Positive mature survival signal from INSIGHT-003 supports further NSCLC investigation: The investigator-initiated Phase I INSIGHT-003 study evaluating efti + pembrolizumab + chemotherapy in first-line nonsquamous NSCLC reported median overall survival of 30.9 months in both the overall population (N=51) and patients with PD-L1 TPS <50% (N=47). Approximately 92% of patients had PD-L1 TPS <50%, suggesting activity in a population that can have limited benefit from PD-1 monotherapy. These results are encouraging, although they come from a small, single-arm Phase I study and cannot establish comparative efficacy.

3. Systematic analysis suggests a biomarker-linked survival effect across tumor types: At ASCO 2026, Immutep reported a systematic evaluation of 592 patients across five clinical trials covering NSCLC, head and neck cancer, metastatic breast cancer and melanoma. Treatment with 30 mg subcutaneous efti plus standard therapy increased circulating absolute lymphocyte counts, and patients classified as ALC responders had a 7.7-month median OS advantage versus non-responders (p=0.0017). The association was observed across tumor types and independently of the combination partner, potentially supporting the use of immune activation biomarkers for future development.

4. Soft-tissue sarcoma provides a differentiated orphan-disease opportunity: The Phase II EFTISARC-NEO study of efti + pembrolizumab + radiotherapy in resectable soft-tissue sarcoma achieved its primary endpoint, producing 51.5% median tumor hyalinization/fibrosis (N=38 evaluable patients; p<0.001)—more than three times the historical 15% figure associated with radiotherapy alone. In April 2026, the FDA granted Orphan Drug Designation to efti for soft-tissue sarcoma. ODD can provide regulatory-development support, potential tax credits/fee exemptions and, if approved, seven years of US market exclusivity.

5. Breast cancer offers another potential development path: Efti is being investigated in AIPAC-003, a Phase II study combining efti with chemotherapy in metastatic HER2-negative/low breast cancer resistant to endocrine therapy and in TNBC. Earlier AIPAC experience demonstrated immune activation and encouraging antitumor activity; in the company's reported Phase II dataset, ORR/DCR were 41.9%/87.1% with 30 mg efti and 48.5%/78.8% with 90 mg in evaluable patients. The program's potential value comes from applying efti's immune-priming mechanism to an underserved population, although these data are not sufficient to establish efficacy versus standard therapy.

Eftilagimod alpha Recent Developments

In December 2025, Immutep Limited, a late-stage immunotherapy company targeting cancer and autoimmune diseases and Dr. Reddy’s Laboratories Ltd., announced that their respective wholly-owned subsidiaries, Immutep SAS and Dr. Reddy’s Laboratories SA, entered into a strategic collaboration and exclusive licensing agreement for the development and commercialisation of Eftilagimod Alfa (efti) in all countries outside North America, Europe, Japan, and Greater China.

“Eftilagimod alpha Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Eftilagimod alpha for potential indication like Non-small cell lung cancer, Breast cancer, COVID 2019 infections, HER2 negative breast cancer, Soft tissue sarcoma, and Squamous cell cancer in the 7MM. A detailed picture of Eftilagimod alpha’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Eftilagimod alpha for potential indications. The Eftilagimod alpha market report provides insights about Eftilagimod alpha’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Eftilagimod alpha performance, future market assessments inclusive of the Eftilagimod alpha market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Eftilagimod alpha sales forecasts, along with factors driving its market.

Eftilagimod alpha Drug Summary

Eftilagimod alpha is an investigational soluble LAG-3 protein-based immunotherapy developed by Immutep that functions as an antigen-presenting cell (APC) activator rather than a conventional immune-checkpoint inhibitor. It binds to MHC class II molecules on antigen-presenting cells, promoting their activation and enhancing the presentation of tumor antigens, which can stimulate both innate and adaptive immune responses, including CD4+ and CD8+ T-cell activity. Eftilagimod alpha is administered by subcutaneous injection and has been investigated in combination with immune checkpoint inhibitors such as pembrolizumab and chemotherapy across several solid tumors, particularly non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC). Its development is based on the potential to convert immunologically “cold” tumors into more responsive environments and enhance the efficacy of PD-1/PD-L1 blockade; however, the program remains investigational and its clinical development has experienced mixed results across trials. The report provides Eftilagimod alpha’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Eftilagimod alpha Market Report

The report provides insights into:

• A comprehensive product overview including the Eftilagimod alpha MoA, description, dosage and administration, research and development activities in potential indication like Non-small cell lung cancer, Breast cancer, COVID 2019 infections, HER2 negative breast cancer, Soft tissue sarcoma, and Squamous cell cancer.
• Elaborated details on Eftilagimod alpha regulatory milestones and other development activities have been provided in Eftilagimod alpha market report.
• The report also highlights Eftilagimod alpha‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The Eftilagimod alpha market report also covers the patents information, generic entry and impact on cost cut.
• The Eftilagimod alpha market report contains current and forecasted Eftilagimod alpha sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Eftilagimod alpha market report also features the SWOT analysis with analyst views for Eftilagimod alpha in potential indications.

Methodology

The Eftilagimod alpha market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Eftilagimod alpha Analytical Perspective by DelveInsight

• In-depth Eftilagimod alpha Market Assessment

This Eftilagimod alpha sales market forecast report provides a detailed market assessment of Eftilagimod alpha for potential indication like Non-small cell lung cancer, Breast cancer, COVID 2019 infections, HER2 negative breast cancer, Soft tissue sarcoma, and Squamous cell cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Eftilagimod alpha sales data uptil 2034.

• Eftilagimod alpha Clinical Assessment

The Eftilagimod alpha market report provides the clinical trials information of Eftilagimod alpha for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Eftilagimod alpha Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Eftilagimod alpha Market Potential & Revenue Forecast

• Projected market size for the Eftilagimod alpha and its key indications
• Estimated Eftilagimod alpha sales potential (Eftilagimod alpha peak sales forecasts)
• Eftilagimod alpha Pricing strategies and reimbursement landscape

Eftilagimod alpha Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Eftilagimod alpha Market positioning compared to existing treatments
• Eftilagimod alpha Strengths & weaknesses relative to competitors

Eftilagimod alpha Regulatory & Commercial Milestones

• Eftilagimod alpha Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Eftilagimod alpha Clinical Differentiation

• Eftilagimod alpha Efficacy & safety advantages over existing drugs
• Eftilagimod alpha Unique selling points

Eftilagimod alpha Market Report Highlights

• In the coming years, the Eftilagimod alpha market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Eftilagimod alpha companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Eftilagimod alpha’s dominance.
• Other emerging products for Non-small cell lung cancer, Breast cancer, COVID 2019 infections, HER2 negative breast cancer, Soft tissue sarcoma, and Squamous cell cancer are expected to give tough market competition to Eftilagimod alpha and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Eftilagimod alpha in potential indications.
• Analyse Eftilagimod alpha cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Eftilagimod alpha sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Eftilagimod alpha in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of Eftilagimod alpha? How strong is Eftilagimod alpha’s clinical and commercial performance?
• What is Eftilagimod alpha’s clinical trial status in each individual indications such as Non-small cell lung cancer, Breast cancer, COVID 2019 infections, HER2 negative breast cancer, Soft tissue sarcoma, and Squamous cell cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Eftilagimod alpha Manufacturers?
• What are the key designations that have been granted to Eftilagimod alpha for potential indications? How are they going to impact Eftilagimod alpha’s penetration in various geographies?
• What is the current and forecasted Eftilagimod alpha market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Eftilagimod alpha in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Eftilagimod alpha for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is Eftilagimod alpha? What is the duration of therapy and what are the geographical variations in cost per patient?